UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2020.
Commission File Number 001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrants name into English)
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On February 26, 2020, Summit Therapeutics plc (the Company) announced that it appointed Robert W. Duggan as Executive Chairman of the Board of Directors of the Company (the Board) with immediate effect. Glyn Edwards will continue as Executive Director and Chief Executive Officer of the Company.
This Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statement on Form F-3 (File No. 333-232074).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SUMMIT THERAPEUTICS PLC | ||||
Date: February 26, 2020 | By: | /s/ Glyn Edwards | ||
Glyn Edwards Chief Executive Officer |
Exhibit 99.1
Summit Therapeutics plc
(Summit or the Company)
Summit Appoints Robert W. Duggan as Executive Chairman
Oxford, UK, and Cambridge, MA, US, 26 February 2020 Summit Therapeutics plc (NASDAQ: SMMT) today announces it has appointed Robert W. Duggan as Executive Chairman of the Board of Directors with immediate effect. Glyn Edwards will continue as an Executive Director and Chief Executive Officer.
Mr Duggan has a track record of building successful commercial organisations aimed at bettering peoples lives, said Mr Glyn Edwards, Chief Executive Officer of Summit. We believe his guidance will help us ensure our targeted antibiotic product candidate ridinilazole has the best opportunity to reach patients with C. difficile infection who desperately need novel treatment options.
Targeted antibiotics have the potential to improve the way infectious diseases are treated by targeting the infectious bacteria and minimising the damage of the healthy and protective microbiome. In C. difficile infection, the selective targeting of the infectious bacteria has significant potential to reduce recurrence and improve patient outcomes, commented Mr Robert W. Duggan. I look forward to being part of the Summit team to realise the full potential of these medicines in bettering patients lives.
About Robert W. Duggan
Mr Robert W. Duggan is a serial US based entrepreneur who has built several successful companies across different industries, including biotechnology. Mr Duggan is currently the Chief Executive Officer of Duggan Investment Inc., a private US investment firm, and a member of the board of directors of Summit. Mr Duggan has served on the boards of a number of US public and private companies and he is currently chairman of the board of the Nasdaq listed company, Pulse Biosciences, Inc. He was previously a substantial shareholder in and the Chairman of the Board and Chief Executive Officer of Pharmacyclics, Inc., which was sold to AbbVie Inc. in 2015. Previously, he was the Chairman of the Board and Chief Executive Officer of Computer Motion, Inc., which later merged with Intuitive Surgical, Inc.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, Enterobacteriaceae and N. gonorrhoeae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
Contacts
Summit |
||||
Glyn Edwards / Richard Pye (UK office) |
Tel: | 44 (0)1235 443 951 | ||
Michelle Avery (US office) |
+1 617 225 4455 | |||
MSL Group (US media) |
Tel: | +1 781 684 6552 | ||
Erin Anthoine |
summit@mslgroup.com | |||
Consilium Strategic Communications (UK media) |
Tel: | +44 (0)20 3709 5700 | ||
Mary-Jane Elliott / Sue Stuart / Sukaina Virji |
summit@consilium-comms.com | |||
Lindsey Neville |
Summit Forward-looking Statements
Any statements in this press release about the Companys future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Companys product candidates, the therapeutic potential of the Companys product candidates, the potential commercialisation of the Companys product candidates, the sufficiency of the Companys cash resources, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals and other statements containing the words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, would, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Companys foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the Risk Factors section of filings that the Company makes with the Securities and Exchange Commission, including the Companys Annual Report on Form 20-F for the fiscal year ended 31 January 2019. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Companys views only as of the date of this release and should not be relied upon as representing the Companys views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.
-END-